Balyasny Asset Management
CLYM

Balyasny Asset Management’s Climb Bio CLYM Stock Holding History

Balyasny Asset Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,959
Closed -$47.7K – 3596
2026
Q1 		$47.7K Sell
6,959
-7,277
-51% -$42K ﹤0.01% 2778
2025
Q4 		$56.9K Buy
+14,236
New +$34.2K ﹤0.01% 3004

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management's CLYM Position: Q2 2026 in Review

Balyasny Asset Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 6,959 shares — an estimated $47.7K sold.

Balyasny Asset Management first reported a position in CLYM in Q4 2025 and held it in 2 quarters. The position peaked at $56.9K in Q4 2025. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Balyasny Asset Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 6,959 Climb Bio shares in Q2 2026, an estimated $47.7K.
  • Balyasny Asset Management first reported a position in Climb Bio in Q4 2025 and held it in 2 quarters.
  • Balyasny Asset Management's Climb Bio position peaked at $56.9K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.